30 Jan Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics
MADISON, Wis.–(BUSINESS WIRE)–Orion Corporation (“Orion”), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body® platform.
Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to optimized panels of bispecific leads. Orion will be responsible for the selection of targets and will be solely responsible for the development, manufacturing, and global commercialization of these candidates. The agreement provides Orion with commercial licenses for up to two bispecific antibodies.
“This collaboration highlights the strength and versatility of our B-Body® platform in addressing complex biological challenges,” said Roland Green, CEO of Invenra. “We are thrilled to work with Orion, a company that shares our commitment to delivering innovative therapies that address critical unmet medical needs.”
“Partnering with Invenra represents an important step in Orion’s strategy to expand our portfolio in the bispecific antibody space,” said Antti Haapalinna, Vice President, Head of External Science & Partnering R&D, Orion. “Invenra’s cutting-edge bispecific discovery platform, combined with Orion’s expertise in development and commercialization, will accelerate the creation of impactful new therapies for patients worldwide.”